Lyell Immunopharma
This microcap biotech also could be a huge home run aggressive traders. Lyell Immunopharma (NASDAQ: LYEL) is a T cell reprogramming company engaged in developing T cell therapies for patients with solid tumors.
The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion, and Epi-R, an ex vivo epigenetic reprogramming technology to generate a population of T cells with durable stemness.
Lyell Immunopharma’s pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845 for multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications.
The Goldman Sachs price target is $21, while the consensus target is $22. The shares trading at $4.05 on Friday, hitting the Goldman Sachs target would be a gain of about 450%.
Taysha Gene Therapies
This company went public in 2020 and was trading close to $30 a share before it was clobbered. Taysha Gene Therapies Inc. (NASDAQ: TSHA) focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system, including the following:
- TSHA-120 for the treatment of giant axonal neuropathy
- TSHA-102 for the treatment of Rett syndrome
- TSHA-121 for the treatment of CLN1 disease
- TSHA-118 for the treatment of CLN1 disease
- TSHA-105 for the treatment of SLC13A5 deficiency
- TSHA-101 for the treatment of GM2 gangliosidosis
Goldman Sachs has a $27 target price. The $25.50 consensus target is also well above the share price of $2.95 seen on Friday. The Goldman Sachs target represents about a 790% gain.
Zevia PBC
This is another micro-cap idea with incredible upside potential. Zevia PBC (NYSE: ZVIA) is a beverage company that develops, markets, sells and distributes various carbonated and non-carbonated soft drinks in the United States and Canada.
Its products include soda, energy drinks, organic tea, mixers, kidz beverages and sparkling water under the Zevia brand name. The company offers its products through various retail channels, including grocery distributors, national retailers, warehouse club and natural products retailers, as well as e-commerce channels.
The company is focused on addressing the global health challenges resulting from excess sugar consumption by offering a broad portfolio of zero sugar, zero calorie, naturally sweetened beverages. All Zevia beverages are made with a handful of simple, plant-based ingredients, contain no artificial sweeteners and are Non-GMO Project verified, gluten-free, Kosher, vegan and zero sodium.
The $14 price target at Goldman Sachs compares with an $11.27 consensus target and Friday’s share price of $2.00. Hitting the Goldman Sachs target would be a 550% gain.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with absolutely no track record or liquidity, and major Wall Street firms have research coverage.
Originally posted at 24/7 Wall St.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
